Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.

[1]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[2]  C R Benedict,et al.  Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. , 1996, Circulation.

[3]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[4]  P. Binkley,et al.  Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration. , 1994, American heart journal.

[5]  O. Vuolteenaho,et al.  Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction. , 1994, American heart journal.

[6]  S. Yusuf,et al.  Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. , 1994, Journal of the American College of Cardiology.

[7]  G. Lamas,et al.  N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. , 1994, Circulation.

[8]  S. Snapinn,et al.  The plasma concentration of N‐terminal proatrial natriuretic factor anf (1‐98) is related to prognosis in severe heart failure , 1994, Clinical cardiology.

[9]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[10]  M. Fisher,et al.  Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. , 1993, Journal of the American College of Cardiology.

[11]  B. Massie,et al.  Can Further Benefit Be Achieved by Adding Flosequinan to Patients With Congestive Heart Failure Who Remain Symptomatic on Diuretic, Digoxin, and an Angiotensin Converting Enzyme Inhibitor? Results of the Flosequinan‐ACE Inhibitor Trial (FACET) , 1993, Circulation.

[12]  B. Massie,et al.  Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. , 1993, Journal of the American College of Cardiology.

[13]  K. Bailey,et al.  Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction , 1993, The Lancet.

[14]  Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure. , 1992, Journal of the American College of Cardiology.

[15]  C. Boucher,et al.  Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure. , 1992, Journal of the American College of Cardiology.

[16]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[17]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[18]  T. LeJemtel,et al.  Flosequinan: a vasodilator with positive inotropic activity. , 1991, American heart journal.

[19]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[20]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[21]  C. Leier,et al.  Chronic vasodilator therapy with flosequinan in congestive heart failure , 1990, Clinical cardiology.

[22]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[23]  C. Stanford,et al.  Effect of flosequinan on exercise capacity and symptoms in severe heart failure. , 1989, British heart journal.

[24]  J. Hampton,et al.  Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects. , 1988, BMJ.

[25]  M. Packer,et al.  Cumulative Hemodynamic Response to Short‐Term Treatment with Flosequinan (BTS 49465), a New Direct‐Acting Vasodilator Drug, in Severe Chronic Congestive Heart Failure , 1988, Journal of cardiovascular pharmacology.

[26]  M. Packer,et al.  Neurohormonal interactions and adaptations in congestive heart failure. , 1988, Circulation.

[27]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[28]  J. Cohn,et al.  Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. , 1987, American heart journal.

[29]  M. Packer,et al.  Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. , 1987, American heart journal.

[30]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[31]  M. Brody,et al.  Evidence for a central role for vasopressin in cardiovascular regulation. , 1983, The American journal of physiology.

[32]  J. Peuler,et al.  Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. , 1977, Life sciences.